Novo Nordisk A/S (NYSE:NVO – Get Rating) shares saw unusually-strong trading volume on Monday . Approximately 2,033,579 shares were traded during mid-day trading, an increase of 44% from the previous session’s volume of 1,407,737 shares.The stock last traded at $170.09 and had previously closed at $170.54.
Analyst Ratings Changes
NVO has been the subject of a number of analyst reports. Credit Suisse Group upgraded Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Thursday, April 13th. StockNews.com assumed coverage on shares of Novo Nordisk A/S in a report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average target price of $383.33.
Novo Nordisk A/S Trading Down 4.1 %
The company has a market capitalization of $369.95 billion, a price-to-earnings ratio of 43.02, a P/E/G ratio of 1.62 and a beta of 0.48. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.86 and a quick ratio of 0.67. The business’s 50-day moving average price is $161.72 and its two-hundred day moving average price is $143.13.
Institutional Inflows and Outflows
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.
- Get a free copy of the StockNews.com research report on Novo Nordisk A/S (NVO)
- Will Fed Rate-Hike Pause Lead To Small-Cap Outperformance?
- The Market Has Taken To GE’s Transformation, Should You?
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.